Date: July 21, 2018 @ 1:00 pm – @ 5:00 pm
Location: Stanford University, Graduate Community Center, Havana Room, 750 Escondido Rd., Palo Alto, CA 94305
1:00 – 1:15 Registration
1:15 – 1:45 Dr. Jack Chen (Principal Scientist, Pfizer)
Sweet and sour of immunotherapy: how to leverage success, overcome resistance, and develop combination therapeutics.
1:45 – 2:15 Dr. Changyu Wang (CEO, Huamian Biotechnology)
Cancer Immunotherapy, PD-1 and beyond.
2:15 – 2:45 Dr. Ute Hoch (Executive Director, Nektar Therapeutics)
Harnessing Potent Immune Agonist Pathways for Oncology
Dr. Ute Hoch is the head of clinical pharmacology and pharmacometrics at Nektar Therapeutics. She obtained her PhD at the University of Wuerzburg, Germany, and completed a post-doctoral fellowship at UCSF. Prior to joining Nektar Therapeutics, she has held leadership positions at Sunesis Pharmaceuticals, GeneSoft and Kosan Biosciences. She has 15+ years’ experience developing innovative small and large molecule therapeutics.
2:45 – 3:00 Break
3:00 – 3:30. Dr. Juliana Idoyaga (Assistant Professor, Stanford University)
3:30 – 4:00. Dr. Hong Wan (CSO, ALX Oncology Inc.)
Targeting CD47 with high affinity SIRPa fusion protein to enhance both innate and adaptive immunity against cancer without hematological toxicity.
4:00 – 5:00 Panel Discussion
This event is co-organized by CABS and CBA.
CABS members – $0 (USD)
Non-members – $10 (USD)